INBX

Inhibrx Biosciences, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 2007919Held by 3 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$1.0M

Net Income FY2025

$(140.0M)

EPS (Basic, as reported)

$-9.04

Net Margin FY2025

-10773.5%

ROE FY2025

-1752.2%

Total Equity

$8.0M

Shares Out

15M

Business description

Inhibrx Biosciences, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2023–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 2 → 1 -29.3% CAGR

Fiscal yearFY2023FY2024FY2025

Revenue201

Research & development(192)(204)(113)

General & administrative(29)(128)(23)

Total operating expenses(221)(332)(136)

Operating income(219)(331)(135)

Interest expense(32)(13)(12)

Other income (expense), net(21)2,019(5)

Pre-tax income(240)1,688(140)

Income tax expense000

Net income(241)1,688(140)

EPS — basic($20.48)$114.01($9.04)

EPS — diluted($20.48)$112.62($9.04)

Shares outstanding — basic (M)121515

Shares outstanding — diluted (M)121515

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.